沃森生物(300142.SZ)：冻干带状疱疹病毒mRNA疫苗获药物临床试验批准

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiaries have received approval from the National Medical Products Administration for a clinical trial of a freeze-dried mRNA vaccine for herpes zoster, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd [1] Group 1 - The clinical trial approval was granted for the freeze-dried herpes zoster virus mRNA vaccine, which is intended for the prevention of herpes zoster [1] - The vaccine application was reviewed and found to meet the requirements for drug registration, with the trial set to commence [1] - The approval notification was issued on September 18, 2025, indicating a timeline for the clinical trial process [1]